|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30.04.26 - 22:21
|
Bio-Rad Reports First-Quarter 2026 Financial Results (Business Wire)
|
|
|
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2026.
Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, stated: "Our first-quarter results reflected our resolve in navigating a dynamic environment. Despite external headwinds including challenging academic end markets and conflict escalation in the Middle East, reported sales grew 1.1% year-over-year. Against this backdrop, we generated strong operating cash flow, $78 million in free cash flow, and repurchased approximately 176 thousand shares, highlighting the quality and long-term durability of our business. We continue to evaluate and optimize our organization to create more value for customers, and ultimately, shareholders."
Financial Results Highlights
GAAP Results
Q1 2026
Q1 2025
Net sales (millions)
$
592.1
$
585.4
Gross margin
52...
|
|
|
16.04.26 - 22:18
|
Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026 (Business Wire)
|
|
|
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2026 on Thursday, April 30, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day.
To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live webcast of the conference call will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available for up to a year.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operat...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13.02.26 - 00:00
|
Bio-Rad Laboratories Swings To Q4 Profit (AFX)
|
|
|
WASHINGTON (dpa-AFX) - Bio-Rad Laboratories, Inc. (BIO), a life science and diagnostic company, on Thursday, reported strong financial performance for the fourth quarter and full year 2025. The co......
|
|
|
|
|
12.02.26 - 22:21
|
Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results (Business Wire)
|
|
|
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025.
Norman Schwartz, Bio-Rad's Chief Executive Officer, stated: “2025 was a challenging year with geopolitical uncertainty and continued pressure on academic research funding affecting our end markets. While we delivered modest revenue growth and strong free cash flow, our gross and operating margin performance fell below our expectations. The recent acquisition of digital PCR developer Stilla Technologies has been successfully integrated, and we are pleased with the initial market adoption of our expanded ddPCR™ product portfolio. As we enter 2026, we remain committed to improving overall performance.”
Financial Results Highlights
GAAP Results
Q4 2025
Q4 2024
Full-Year 2025
Full-Year 2024
Revenue (millions)
$
693.2
$
667.5
$
2,583.2
$
2,...
|
|
|
29.01.26 - 14:36
|
Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026 (Business Wire)
|
|
|
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year 2025 on Thursday, February 12, 2026, following the close of the market. Management will discuss these results in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) that day.
To participate, dial (800) 715-9871 within the U.S. or (646) 307-1963 outside the U.S., access code: 9562470. A live webcast of the conference call, as well as a supplemental earnings presentation, will also be available in the "Investor Relations" section of the company's website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast will be available for up to a year.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical d...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
